News

Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Abdera Therapeutics to Present at the 43rd Annual J.P Morgan Healthcare Conference

Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

Fierce Biotech Names Abdera Therapeutics a “Fierce 15” Biotech Company of 2024

Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

Abdera Therapeutics Expands Management Team and Board of Directors

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer